Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135


Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.

Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, Gilmer TM.

Mol Cancer Ther. 2007 May;6(5):1629-40.


Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL.

Cancer Res. 2007 Feb 1;67(3):1170-5.


Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.

O'Neill F, Madden SF, Aherne ST, Clynes M, Crown J, Doolan P, O'Connor R.

Mol Cancer. 2012 Jun 18;11:41. doi: 10.1186/1476-4598-11-41.


Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL.

Cancer Res. 2006 Feb 1;66(3):1640-7.


Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.

Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51. doi: 10.1016/j.ejphar.2008.06.026. Epub 2008 Jun 12.


Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.


Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.

Vannini I, Zoli W, Fabbri F, Ulivi P, Tesei A, Carloni S, Brigliadori G, Amadori D.

Anticancer Drugs. 2009 Nov;20(10):918-25. doi: 10.1097/CAD.0b013e32833179bf.


Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, Moseley MA 3rd, Thompson JW, Chen FL, Koch KM, Spector NL.

Mol Cancer Ther. 2010 Feb;9(2):292-9. doi: 10.1158/1535-7163.MCT-09-1041. Epub 2010 Feb 2.


The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.


Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.

Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.


Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.

Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K, Zhang G.

Mol Cancer. 2009 Oct 1;8:81. doi: 10.1186/1476-4598-8-81.


Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.

Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao M, Garattini E.

Oncogene. 2012 Jul 19;31(29):3431-43. doi: 10.1038/onc.2011.506. Epub 2011 Nov 7.


Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines.

Hevir N, Trošt N, Debeljak N, Rižner TL.

Chem Biol Interact. 2011 May 30;191(1-3):206-16. doi: 10.1016/j.cbi.2010.12.013. Epub 2010 Dec 21.

Items per page

Supplemental Content

Write to the Help Desk